Literature DB >> 28872996

American Society of Clinical Oncology Statement on the Impact of Utilization Management Policies for Cancer Drug Therapies.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28872996     DOI： 10.1200/JOP.2017.024273

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  6 in total

Review 1.  Impact of Pharmacy Benefit Managers on Oncology Practices and Patients.

Authors:  Trevor J Royce; Caroline Schenkel; Kelsey Kirkwood; Laura Levit; Kathryn Levit; Sheetal Kircher
Journal:  JCO Oncol Pract       Date:  2020-04-20

2.  Patient, provider, and hospital factors associated with oral anti-neoplastic agent initiation and adherence in older patients with metastatic renal cell carcinoma.

Authors:  Deborah R Kaye; Lauren E Wilson; Melissa A Greiner; Lisa P Spees; Jessica E Pritchard; Tian Zhang; Craig E Pollack; Daniel George; Charles D Scales; Chris D Baggett; Cary P Gross; Michael S Leapman; Stephanie B Wheeler; Michaela A Dinan
Journal:  J Geriatr Oncol       Date:  2022-02-04       Impact factor: 3.929

3.  Association of Utilization Management Policy With Uptake of Hypofractionated Radiotherapy Among Patients With Early-Stage Breast Cancer.

Authors:  Ravi B Parikh; Ezra Fishman; Winnie Chi; Robert P Zimmerman; Atul Gupta; John J Barron; Gosia Sylwestrzak; Justin E Bekelman
Journal:  JAMA Oncol       Date:  2020-06-01       Impact factor: 31.777

4.  Why individual-level interventions are not enough: Systems-level determinants of oral anticancer medication adherence.

Authors:  Lorraine T Dean; Marshalee George; Kimberley T Lee; Kimlin Ashing
Journal:  Cancer       Date:  2020-05-21       Impact factor: 6.860

5.  Factors Affecting Usage Levels and Trends of Innovative Oncology Drugs Upon and After Reimbursement Under Taiwan National Health Insurance: Interrupted Time Series Analysis.

Authors:  Kai-Hsin Liao; Bor-Sheng Ko; Liang-Kung Chen; Fei-Yuan Hsiao
Journal:  Clin Transl Sci       Date:  2020-07-16       Impact factor: 4.689

6.  Low Bioavailability and High Immunogenicity of a New Brand of E. colil-Asparaginase with Active Host Contaminating Proteins.

Authors:  Priscila Pini Zenatti; Natacha Azussa Migita; Nathália Moreno Cury; Rosângela Aparecida Mendes-Silva; Fabio Cesar Gozzo; Pedro Otavio de Campos-Lima; José Andrés Yunes; Silvia Regina Brandalise
Journal:  EBioMedicine       Date:  2018-03-09       Impact factor: 8.143
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.